Loading
Life sciences · Journal article
Journal of Medicinal Chemistry and Therapeutics · August 16, 2026
Raises a question worth testing. It does not answer one.
This is a systematic review of the phytochemistry and pharmacology of Quisqualis indica, a traditional medicinal plant used in Asian and African medicine. The review identifies diverse in vitro and animal-model evidence of antioxidant, anticancer, antibacterial, anti-inflammatory, antimalarial, anti-obesity, and neuropharmacological activities, but acknowledges severe limitations in phytochemical standardization, extraction consistency, reliance on preclinical models, and a critical paucity of human clinical trials. The evidence base is too fragmented and methodologically heterogeneous to support clinical translation without substantial additional research.
Systematic review following PRISMA 2020 guidelines. Studies on Quisqualis indica L. examining its phytochemical composition and pharmacological activities; no restriction to a specific human population. Setting and key eligibility criteria not detailed in abstract.. Intervention: Quisqualis indica L., its extracts, and bioactive components (flavonoids, polyphenols, tannins, cucurbitacin derivatives, trigonelline, quisqualic acid).
642 records identified; 154 duplicates removed; 488 screened; 140 assessed for eligibility; 76 studies included in qualitative synthesis Experimental results demonstrate antioxidant, anticancer, antibacterial, anti-inflammatory, antimalarial, anti-obesity, and neuropharmacological activities in preclinical models Severe flaws identified: insufficient phytochemical standardisation, inconsistent extraction methodologies, overreliance on in vitro and animal models, scarcity of quality clinical trials
Scarcity of human clinical trials means no efficacy or safety data in the target population Experimental results demonstrate antioxidant, anticancer, antibacterial, anti-inflammatory, antimalarial, anti-obesity, and neuropharmacological activities in preclinical models
Clinicians and researchers should recognize that Q. indica has not been adequately evaluated in humans; current evidence is insufficient to support clinical use for any indication. The review identifies a research agenda rather than actionable clinical findings, and highlights the need for standardized phytochemical analysis, rigorous pharmacokinetic studies, and well-designed clinical trials before any therapeutic claims can be substantiated.
A systematic review of predominantly preclinical and in vitro evidence on a medicinal plant with acknowledged severe methodological flaws, insufficient standardization, and a scarcity of clinical trials; raises mechanistic questions rather than answering translational ones.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians and researchers should recognize that Q. indica has not been adequately evaluated in humans; current evidence is insufficient to support clinical use for any indication. The review identifies a research agenda rather than actionable clinical findings, and highlights the need for standardized phytochemical analysis, rigorous pharmacokinetic studies, and well-designed clinical trials before any therapeutic claims can be substantiated.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Quisqualis indica L. is a promising medicinal plant due to its diverse pharmacological activities and phytochemical composition. Although it has long been used in Asian and African ethnomedicine to treat gastrointestinal issues, metabolic problems, parasite infections, and inflammatory disorders, current research on its therapeutic potential is fragmented and methodologically inconsistent. This review critically evaluates the current literature on the phytochemistry, pharmacological activities, and therapeutic potential of Q. indica, focusing on the mechanistic functions of the plant's main bioactive components, flavonoids, polyphenols, tannins, cucurbitacin derivatives, trigonelline, and quisqualic acid. A systematic literature search following PRISMA 2020 guidelines was conducted using PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar (database inception to 30 June 2026). Of 642 records identified, 154 duplicates were removed; 488 records were screened, 140 full-text articles were assessed for eligibility, and 76 studies were ultimately included in the qualitative synthesis. Experimental results show that Q. indica has significant antioxidant, anticancer, antibacterial, anti-inflammatory, antimalarial, anti-obesity, and neuropharmacological activities by regulating oxidative stress, apoptosis, inflammatory mediators, microbial growth, and metabolic signalling pathways. However, a detailed evaluation of the existing data finds severe flaws, such as insufficient phytochemical standardisation, inconsistent extraction methodologies, an overreliance on in vitro and animal models, and a scarcity of quality clinical trials. A paucity of evidence on pharmacokinetics, bioavailability, long-term toxicity, and herb-drug interactions further limits translational applicability. Despite these limitations, combining advanced analytical techniques, nanotechnology-based delivery technologies, and mechanism-driven pharmacological research may enhance the therapeutic potential of compounds obtained from Q. indica. Overall, this review stresses Q. indica's therapeutic significance while highlighting significant research gaps that must be addressed before its bioactive constituents can be translated into evidence-based phytopharmaceutical medicines.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.